Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Weber, P; Thonhofer, M; Averill, S; Davies, GJ; Santana, AG; Müller, P; Nasseri, SA; Offen, WA; Pabst, BM; Paschke, E; Schalli, M; Torvisco, A; Tschernutter, M; Tysoe, C; Windischhofer, W; Withers, SG; Wolfsgruber, A; Wrodnigg, TM; Stütz, AE.
Mechanistic Insights into the Chaperoning of Human Lysosomal-Galactosidase Activity: Highly Functionalized Aminocyclopentanes and C-5a-Substituted Derivatives of 4-epi-Isofagomine.
Molecules. 2020; 25(17):
Doi: 10.3390/molecules25174025
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Pabst Bettina
-
Paschke Eduard
-
Schalli Michael
-
Tschernutter Marion
-
Windischhofer Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Glycosidase inhibitors have shown great potential as pharmacological chaperones for lysosomal storage diseases. In light of this, a series of new cyclopentanoid β-galactosidase inhibitors were prepared and their inhibitory and pharmacological chaperoning activities determined and compared with those of lipophilic analogs of the potent β-d-galactosidase inhibitor 4-epi-isofagomine. Structure-activity relationships were investigated by X-ray crystallography as well as by alterations in the cyclopentane moiety such as deoxygenation and replacement by fluorine of a "strategic" hydroxyl group. New compounds have revealed highly promising activities with a range of β-galactosidase-compromised human cell lines and may serve as leads towards new pharmacological chaperones for GM1-gangliosidosis and Morquio B disease.
- Find related publications in this database (Keywords)
-
iminoalditol
-
4-epi-isofagomine
-
carbasugar
-
aminocyclopentane
-
galactosidase inhibitor
-
pharmacological chaperone
-
G(M1)-gangliosidosis